Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

Pharma Tech

CSL and Alentis ink $1.5bn partnership to progress antifibrotic drug

Oct 6, 2026, 9:54 AM

Read Full Article → CSL and Alentis ink $1.5bn partnership to progress antifibrotic drug

CSL and Alentis ink $1.5bn partnership to progress antifibrotic drug

Translate article text

Choose a language and wait for the translated text.

CSL and Alentis will work together to progress antifibrotic drug, lixudebart across multiple rare kidney and liver diseases.

CSL and Alentis ink $1.5bn partnership to progress antifibrotic drug | PharmaVoice